Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test.

Abstract:

BACKGROUND:Guaiac-based faecal occult blood tests (g-FOBTs) are most commonly used in colorectal cancer (CRC) screening programmes. Faecal immunochemical tests (FITs) are thought to be superior. AIM:To compare performance of a g-FOBT and a quantitative FIT for detection of CRCs and advanced adenomas in a colonoscopy-controlled population. METHODS:We assessed sensitivity and specificity of both FIT (OC-sensor) and g-FOBT (Hemoccult-II) prior to patients' scheduled colonoscopies. RESULTS:Of the 62 invasive cancers detected in 1821 individuals, g-FOBT was positive in 46 and FIT in 54 (74.2% vs. 87.1%, P = 0.02). Among 194 patients with advanced adenomas, g-FOBT was positive in 35 and FIT in 69 (18.0% vs. 35.6%, P < 0.001). Sensitivity for screen relevant tumours (197 advanced adenomas and 28 stage I or II cancers) was 23.0% for g-FOBT and 40.5% for FIT (P < 0.001). Specificity of g-FOBT compared to FIT for the detection of cancer was 95.7% vs. 91.0%, P < 0.001) and for advanced adenomas (97.4% vs. 94.2%, P < 0.001). CONCLUSIONS:Faecal immunochemical test is more sensitive for CRC and advanced adenomas. Sensitivity of FIT for screen relevant tumours, early-stage cancers and advanced adenomas, is significantly higher. Specificity of g-FOBT is higher compared with FIT.

journal_name

Aliment Pharmacol Ther

authors

Oort FA,Terhaar Sive Droste JS,Van Der Hulst RW,Van Heukelem HA,Loffeld RJ,Wesdorp IC,Van Wanrooij RL,De Baaij L,Mutsaers ER,van der Reijt S,Coupe VM,Berkhof J,Bouman AA,Meijer GA,Mulder CJ

doi

10.1111/j.1365-2036.2009.04184.x

subject

Has Abstract

pub_date

2010-02-01 00:00:00

pages

432-9

issue

3

eissn

0269-2813

issn

1365-2036

pii

APT4184

journal_volume

31

pub_type

杂志文章,多中心研究
  • Classification of dyspepsia and response to treatment with proton-pump inhibitors.

    abstract:BACKGROUND:Lacking an objective 'gold standard' for diagnosing dyspepsia, several symptom-based classifications have been suggested. AIM:To assess if response to proton-pump inhibitor treatment could provide useful information for current or future dyspepsia classification. METHODS:Post hoc analyses of 829 patients t...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2004.02243.x

    authors: Meineche-Schmidt V

    更新日期:2004-11-15 00:00:00

  • One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.

    abstract:BACKGROUND:Triple therapy based upon omeprazole, amoxycillin and clarithromycin for 7 days is the reference treatment used in France for the eradication of Helicobacter pylori. However, optimal dosages of omeprazole and clarithromycin have not been determined. AIMS:To compare four eradication regimens using this treat...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.1998.00315.x

    authors: Bigard MA,Delchier JC,Riachi G,Thibault P,Barthelemy P

    更新日期:1998-04-01 00:00:00

  • Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole.

    abstract:AIM:To determine the effect of Helicobacter pylori eradication with omeprazole and amoxycillin, with or without metronidazole, on the 12-month course of duodenal ulcer disease. METHODS:In a randomized; double-blind study, conducted in 19 hospitals, 105 H. pylori positive duodenal ulcer patients were healed and symptom...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.1996.36178000.x

    authors: Bell GD,Bate CM,Axon AT,Tildesley G,Martin JL,Taylor MD,Richardson PD

    更新日期:1996-08-01 00:00:00

  • How accurate is the determination of blood in gastric juice? Comparison of peroxidase and porphyrin methods.

    abstract:BACKGROUND:Mucosal bleeding is frequently used as a measure of gastric mucosal integrity. We compared the orthotolidine method for quantifying haemoglobin in gastric juice with a method based on measurement of fluorescent porphyrins extracted from haem. We also investigated whether acid or pepsin had a deleterious effe...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.0953-0673.1996.00333.x

    authors: Woods KL,Kiefe C,Graham DY

    更新日期:1996-06-01 00:00:00

  • Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection.

    abstract:BACKGROUND:One-week triple therapy consisting of omeprazole 20 mg b.d., clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. is an effective therapy for H. pylori infection with a cure rate of 93%. We therefore compared two similar 1-week regimens consisting of a lansoprazole, clarithromycin and either metronidazole o...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.0953-0673.1996.00275.x

    authors: Jaup BH,Norrby A

    更新日期:1996-06-01 00:00:00

  • Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea.

    abstract:BACKGROUND:Travellers' diarrhoea, a common problem worldwide with significant medical impact, is generally treated with anti-diarrhoeal agents and fluid replacement. Systemic antibiotics are also used in selected cases, but these may be associated with adverse effects, bacterial resistance and drug-drug interactions. ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2010.04296.x

    authors: Layer P,Andresen V

    更新日期:2010-06-01 00:00:00

  • Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.

    abstract:BACKGROUND:Ustekinumab is a monoclonal antibody targeting interleukins-12 and -23, with efficacy in Crohn's disease (CD) demonstrated in clinical trials. AIM:To assess the real-world clinical, endoscopic and radiographic response and remission outcomes achieved with ustekinumab in medically-refractory CD. METHODS:A r...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.14016

    authors: Ma C,Fedorak RN,Kaplan GG,Dieleman LA,Devlin SM,Stern N,Kroeker KI,Seow CH,Leung Y,Novak KL,Halloran BP,Huang VW,Wong K,Blustein PK,Ghosh S,Panaccione R

    更新日期:2017-05-01 00:00:00

  • Symptomatic improvement with one-year cisapride treatment in neuropathic chronic intestinal dysmotility.

    abstract:AIM:To assess the efficacy of a prokinetic agent in the long-term treatment of chronic intestinal dysmotility and the influence of extrinsic denervation. METHODS:We assessed symptoms, compliance and untoward effects in an open, 1-year trial of cisapride, 20 mg t.d.s., in 37 patients with neuropathic forms of chronic i...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.0953-0673.1996.00403.x

    authors: Camilleri M,Balm RK,Zinsmeister AR

    更新日期:1996-06-01 00:00:00

  • Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children--updated analysis of randomised controlled trials.

    abstract:BACKGROUND:The efficacy of each probiotic should be evaluated separately. Previously, we have shown that Lactobacillus GG (LGG) is effective in treating acute gastroenteritis (AGE) in children. AIM:To update our 2007 meta-analysis on the effectiveness of LGG in treating AGE in children. METHODS:The Cochrane Library, ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/apt.12403

    authors: Szajewska H,Skórka A,Ruszczyński M,Gieruszczak-Białek D

    更新日期:2013-09-01 00:00:00

  • Clinical response after transjugular intrahepatic portosystemic stent shunt insertion for refractory ascites in cirrhosis.

    abstract:BACKGROUND:Transjugular intrahepatic portosystemic stent shunts (TIPSS) have been used successfully to reduce portal pressure in the context of variceal haemorrhage. Recent interest has focused on the possible use of TIPSS to manage refractory ascites. AIM:To study the effect of TIPSS insertion in 18 patients with ref...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1996.60202000.x

    authors: Forrest EH,Stanley AJ,Redhead DN,McGilchrist AJ,Hayes PC

    更新日期:1996-10-01 00:00:00

  • NSAID-associated gastroduodenal damage: does famotidine protection extend into the mid- and distal duodenum?

    abstract::Eighteen healthy volunteers were included in a cross-over, double-blind study where 500 mg naproxen b.d. was given for 1 week with 20 mg famotidine b.d., 40 mg nocte or placebo. Endoscopic evaluation of the gastroduodenal mucosa was performed before and after each treatment period, with separate evaluation of the mid-...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.1990.tb00474.x

    authors: Aabakken L,Bjørnbeth BA,Weberg R,Viksmoen L,Larsen S,Osnes M

    更新日期:1990-06-01 00:00:00

  • Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome.

    abstract:BACKGROUND:Alterations in serotonergic (5-HT) metabolism and/or intestinal integrity have been associated with irritable bowel syndrome (IBS). AIMS:To assess the effects of the precursor of 5-HT, 5-hydroxytryptophan (5-HTP), on mucosal 5-HT availability and intestinal integrity, and to assess potential differences bet...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/apt.12842

    authors: Keszthelyi D,Troost FJ,Jonkers DM,van Eijk HM,Lindsey PJ,Dekker J,Buurman WA,Masclee AA

    更新日期:2014-08-01 00:00:00

  • Review article: the treatment of fatty liver disease associated with the metabolic syndrome.

    abstract::The treatment of non-alcoholic fatty liver disease may be worthwhile to prevent progression to advanced liver failure, but no therapy is definitely evidence-based. Weight loss or lifestyle modifications remain the primary line of intervention, particularly in overweight or obese subjects. In adult non-alcoholic fatty ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2005.02593.x

    authors: Marchesini G,Natale S,Manini R,Agostini F

    更新日期:2005-11-01 00:00:00

  • The role of screening and antibiotic prophylaxis in the prevention of percutaneous gastrostomy site infection caused by methicillin-resistant Staphylococcus aureus.

    abstract:BACKGROUND:Peristomal wound infections are common complications of percutaneous endoscopic gastrostomy (PEG), especially in hospitals where methicillin-resistant Staphylococcus aureus (MRSA) is endemic. Evidence suggests that antibiotic prophylaxis at PEG insertion may reduce infection rates. AIM:To examine rates of p...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.03242.x

    authors: Thomas S,Cantrill S,Waghorn DJ,McIntyre A

    更新日期:2007-03-01 00:00:00

  • Effectiveness and safety of obeticholic acid in a Southern European multicenter cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid.

    abstract:BACKGROUND:Obeticholic acid (OCA) was recently approved as the only on-label alternative for patients with primary biliary cholangitis (PBC) with intolerance or suboptimal response to ursodeoxycholic acid (UDCA). However, few data are available outside clinical trials. AIM:To assess the effectiveness and safety of OCA...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.16181

    authors: Gomez E,Garcia Buey L,Molina E,Casado M,Conde I,Berenguer M,Jorquera F,Simón MA,Olveira A,Hernández-Guerra M,Mesquita M,Presa J,Costa-Moreira P,Macedo G,Arenas JI,Manuel Sousa J,Ampuero J,Morillas RM,Santos A,De Car

    更新日期:2020-12-12 00:00:00

  • Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.

    abstract:BACKGROUND:Combination treatment with azathioprine for 6-12 months is the preferred strategy for starting infliximab due to improved pharmacokinetics. However, optimised infliximab monotherapy with proactive dose escalations in case of low trough levels is a safer but under-studied alternative. AIM:To compare the clin...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15179

    authors: Drobne D,Kurent T,Golob S,Švegl P,Rajar P,Hanžel J,Koželj M,Novak G,Smrekar N,Ferkolj I,Štabuc B

    更新日期:2019-04-01 00:00:00

  • Systematic review: herbal medicinal products for non-ulcer dyspepsia.

    abstract:BACKGROUND:Non-ulcer dyspepsia is predominantly a self-managed condition, although it accounts for a significant number of general practitioner consultations and hospital referrals. Herbal medicinal products are often used for the relief of dyspeptic symptoms. AIMS:: To critically assess the evidence for and against h...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2002.01339.x

    authors: Thompson Coon J,Ernst E

    更新日期:2002-10-01 00:00:00

  • Unanswered questions about Helicobacter pylori.

    abstract::There is general agreement that Helicobacter pylori eradication is indicated in all infected patients with duodenal ulcer disease and is probably indicated in all infected patients with gastric ulcer disease. However, translation of treatment recommendations into practice leads to some difficult clinical decisions. Th...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.1995.tb00781.x

    authors: Walsh JH

    更新日期:1995-01-01 00:00:00

  • Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis--a double-blind, placebo-controlled study.

    abstract:BACKGROUND:Pancreatic exocrine insufficiency (PEI) results in maldigestion, leading to abdominal pain, steatorrhoea, malnutrition and weight loss. AIM:To assess the efficacy and safety of pancreatin (Creon 40000 MMS) in treating PEI due to chronic pancreatitis (CP). METHODS:This was a 1-week, double-blind, randomised...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2012.05202.x

    authors: Thorat V,Reddy N,Bhatia S,Bapaye A,Rajkumar JS,Kini DD,Kalla MM,Ramesh H

    更新日期:2012-09-01 00:00:00

  • A non-toxic analogue of a coeliac-activating gliadin peptide: a basis for immunomodulation?

    abstract:BACKGROUND:A-gliadin residues 31-49 (peptide A) binds to HLA-DQ2 and is toxic to coeliac small bowel. Analogues of this peptide, which bind to DQ2 molecules but are non-toxic, may be a potential route to inducing tolerance to gliadin in patients with coeliac disease. METHODS:Toxicity was investigated with small bowel ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1999.00512.x

    authors: Biagi F,Ellis HJ,Parnell ND,Shidrawi RG,Thomas PD,O'Reilly N,Corazza GR,Ciclitira PJ

    更新日期:1999-07-01 00:00:00

  • Cisapride and ranitidine in the treatment of gastro-oesophageal reflux disease--a comparative randomized double-blind trial.

    abstract::Forty patients with gastro-oesophageal reflux disease and oesophagitis, documented by endoscopy (grades I to III by the Savary-Miller classification) were randomized to participate in a comparative double-blind trial to receive cisapride (10 mg q.d.s.) or ranitidine (150 mg b.d.) for an 8-week period. Upper gastrointe...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1993.tb00145.x

    authors: Arvanitakis C,Nikopoułos A,Theoharidis A,Giannoulis E,Vagios I,Anthopoulou H,Michailidis D,Tourkantonis A

    更新日期:1993-12-01 00:00:00

  • Mucosal penetration and clearance of gluten and milk antigens in eosinophilic oesophagitis.

    abstract:BACKGROUND:The Th2 allergic pathway in eosinophilic oesophagitis (EoE) responds to food antigen exposure. AIM:To compare the presence and temporal pattern of food antigen penetration in oesophageal mucosa in active and inactive EoE and controls METHODS: Thirty-two patients with EoE (20 active) and 10 controls were ask...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.16180

    authors: Ravi A,Marietta EV,Alexander JA,Peterson K,Lavey C,Geno DM,Murray JA,Katzka DA

    更新日期:2021-02-01 00:00:00

  • Colectomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients.

    abstract:BACKGROUND:Despite the close relationship between primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD), the association between colectomy and the prognosis of PSC remains controversial. AIM:To explore whether colectomy prior to PSC-diagnosis is associated with transplant-free survival. METHODS:A ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.14393

    authors: Nordenvall C,Olén O,Nilsson PJ,von Seth E,Ekbom A,Bottai M,Myrelid P,Bergquist A

    更新日期:2018-01-01 00:00:00

  • Meta-analysis: colonoscopic post-polypectomy bleeding in patients on continued clopidogrel therapy.

    abstract:BACKGROUND:Current guidelines recommend the cessation of clopidogrel therapy 5 days and 7-10 days prior to colonoscopic polypectomy. Recent studies have advocated for continued clopidogrel as post-polypectomy bleeding (PPB) rates have been similar to those in the general population not on antithrombotic therapy. AIM:T...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/apt.12292

    authors: Gandhi S,Narula N,Mosleh W,Marshall JK,Farkouh M

    更新日期:2013-05-01 00:00:00

  • Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection.

    abstract:BACKGROUND:HS-10234 is a novel prodrug of tenofovir developed to increase anti-viral potency and to reduce systemic toxicities. AIMS:To evaluate the tolerability, pharmacokinetics and anti-viral efficacy of HS-10234 in patients with chronic hepatitis B (CHB) infection METHODS: Treatment-naïve subjects with non-cirrhot...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.16196

    authors: Zhang H,Hu Y,Wu M,Liu J,Zhu X,Li X,Chen H,Li C,Liu C,Niu J,Ding Y

    更新日期:2021-01-01 00:00:00

  • Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion-a placebo-controlled study in healthy volunteers.

    abstract:BACKGROUND:The new tablet formulation of omeprazole (Losec MUPS), is thought to have a stronger acid inhibition than the previously marketed capsules. METHODS:The effects of the proton pump inhibitors lansoprazole and omeprazole tablets on pentagastrin-stimulated acid secretion were compared in Helicobacter pylori-neg...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.2000.00823.x

    authors: Müller P,Göksu MA,Fuchs W,Schlüter F,Simon B

    更新日期:2000-09-01 00:00:00

  • Combat-training increases intestinal permeability, immune activation and gastrointestinal symptoms in soldiers.

    abstract:BACKGROUND:Gastrointestinal (GI) symptoms are common in soldiers in combat or high-pressure operational situations and often lead to compromised performance. Underlying mechanisms are unclear, but neuroendocrine dysregulation, immune activation and increased intestinal permeability may be involved in stress-related GI ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12269

    authors: Li X,Kan EM,Lu J,Cao Y,Wong RK,Keshavarzian A,Wilder-Smith CH

    更新日期:2013-04-01 00:00:00

  • Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a systemic disorder that predominantly affects the bowels but is also associated with venous thromboembolism (VTE). AIM:To provide a quantitative assessment of the association of IBD with venous thromboembo...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/apt.12294

    authors: Yuhara H,Steinmaus C,Corley D,Koike J,Igarashi M,Suzuki T,Mine T

    更新日期:2013-05-01 00:00:00

  • Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child.

    abstract:BACKGROUND:With the global efforts to eradicate hepatitis C virus (HCV), treatment during pregnancy is becoming a priority for research as this, and maternal cure should reduce vertical transmission. However, as information on the efficacy and safety of direct-acting antivirals (DAAs) in pregnancy is generally lacking,...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.15476

    authors: Freriksen JJM,van Seyen M,Judd A,Gibb DM,Collins IJ,Greupink R,Russel FGM,Drenth JPH,Colbers A,Burger DM

    更新日期:2019-10-01 00:00:00

  • Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease.

    abstract:BACKGROUND:Anti-TNFα agents have revolutionised management of chronic inflammatory diseases. Paradoxically, these agents might provoke development of de novo autoimmune diseases. AIM:To examine whether there is an increased risk of developing Crohn's disease (CD) and ulcerative colitis (UC) while under treatment with ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15370

    authors: Korzenik J,Larsen MD,Nielsen J,Kjeldsen J,Nørgård BM

    更新日期:2019-08-01 00:00:00